アムロジピン中毒における難治性低血圧および遅発性呼吸不全:多面的管理アプローチ
Maria Haq1, Chima Iloanugo2, Rabiu Momoh1
1Critical Care, Medway Maritime Hospital, Gillingham, GBR.
Abstract:
Pulmonary oedema is a rare but possible paradoxical complication following the withdrawal of high-dose insulin euglycemic therapy (HIET). In the context of calcium channel blocker (CCB) toxicity, other potential confounding factors that could account for delayed pulmonary oedema include inadvertent fluid overload from management of hypotension caused by CCB toxicity, delayed toxicodynamic effects on the pulmonary vasculature and the heart, or a previously unknown underlying cardiac dysfunction. We report a case involving a woman in her early 50s who developed a symptomatic pulmonary oedema following the discontinuation of HIET used in the management of refractory hypotension complicating a massive amlodipine intoxication. This unexpected deterioration occurred despite improved haemodynamics following HIET used in the management of amlodipine toxicity. We have reviewed this case in relation to the existing literature on delayed or paradoxical pulmonary oedema complicating CCB toxicity, to the benefit of clinical personnel managing future similar cases.
さらに関連する動画
08:51Multiple Intravenous Bolus Dosing and Invasive Hemodynamic Assessment in a Hypoxia-Induced Mouse Pulmonary Artery Hypertension Model
Published on: November 11, 2022
08:12Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS
Published on: November 26, 2018
関連する概念動画
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Heart Failure Drugs: Inotropic Agents
